Cedars-Sinai Accelerator
Investments
64Portfolio Exits
4About Cedars-Sinai Accelerator
Cedars-Sinai Accelerator is transforming heatlhcare quality, efficiency, and care delivery by helping entrepreneurs bring their innovative technology products to market. This three-month program, based in Los Angeles, California, provides companies with $120,000 in funding, mentorship from more than 300 leading clinicians and executives, access to Cedars-Sinai, and exposure to a network of over 10,000 entrepreneurs and investors.
Cedars-Sinai Accelerator Headquarter Location
8601 Beverly Boulevard
Los Angeles, California, 90048,
United States
Cedars-Sinai Accelerator Web Traffic
Cedars-Sinai Accelerator Rank
Latest Cedars-Sinai Accelerator News
May 20, 2022
An innovative mobile phone application was found to be as good as expert gastroenterologists at characterizing stool specimens, according to a study by Cedars-Sinai. The artificial intelligence (AI) used in the smartphone app also outperformed reports by patients describing their stool specimens. Stool reporting by patients, usually guided by the Bristol Stool Scale, is crucial to helping physicians evaluate symptoms for diagnosis or for judging the effectiveness of medications. Sometimes patients don't know what is normal or abnormal when trying to characterize a bowel movement. This app takes out the guesswork by using AI, not patient input, to process the images taken by the smartphone." Mark Pimentel, MD, principal investigator of the study, executive director of the Medically Associated Science and Technology Program at Cedars-Sinai Related Stories "The mobile app produced more accurate and complete descriptions of constipation, diarrhea and normal stools than a patient could and was comparable to specimen evaluations by well-trained gastroenterologists in the study," said Pimentel, a specialist in irritable bowel syndrome (IBS). The validation study, was published in the American Journal of Gastroenterology and will be presented at the Digestive Disease Week conference in San Diego on May 21. Investigators used a trained AI app for smartphones developed by Dieta Health, a graduate of the Cedars-Sinai Accelerator program that helps entrepreneurs bring their innovative healthcare technology products to market. In a randomized controlled study, participants with diarrhea-predominant IBS, or IBS-D, were asked to use the AI app to take a picture of every stool for two weeks. In addition to the commonly used Bristol Stool Scale, the AI app also incorporates additional classification parameters. Two expert gastroenterologists assessed the images to validate the mobile app. "The artificial intelligence tool removes the subjective description that can be part of a patient's description of their bowel specimens. In addition to improving a physician's ability to assess their patients' digestive health, this app could be advantageous for clinical trials by reducing the variability of stool outcome measures," said Ali Rezaie, MD, co-author of the study and the medical director of GI Motility at Cedars-Sinai. Source:
Cedars-Sinai Accelerator Investments
64 Investments
Cedars-Sinai Accelerator has made 64 investments. Their latest investment was in Rhaeos as part of their Seed VC on December 12, 2021.
Cedars-Sinai Accelerator Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
12/24/2021 | Seed VC | Rhaeos | $2.2M | No | 6 | |
9/28/2021 | Convertible Note | EpiBone | $0.1M | Yes | 1 | |
9/28/2021 | Convertible Note | inTandem Health | $0.1M | Yes | 1 | |
9/28/2021 | Convertible Note | |||||
9/28/2021 | Convertible Note |
Date | 12/24/2021 | 9/28/2021 | 9/28/2021 | 9/28/2021 | 9/28/2021 |
---|---|---|---|---|---|
Round | Seed VC | Convertible Note | Convertible Note | Convertible Note | Convertible Note |
Company | Rhaeos | EpiBone | inTandem Health | ||
Amount | $2.2M | $0.1M | $0.1M | ||
New? | No | Yes | Yes | ||
Co-Investors | |||||
Sources | 6 | 1 | 1 |
Cedars-Sinai Accelerator Portfolio Exits
4 Portfolio Exits
Cedars-Sinai Accelerator has 4 portfolio exits. Their latest portfolio exit was Enso Relief on March 09, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
3/9/2021 | Acquired | 4 | |||
Date | 3/9/2021 | |||
---|---|---|---|---|
Exit | Acquired | |||
Companies | ||||
Valuation | ||||
Acquirer | ||||
Sources | 4 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.